SCHEMBL7814976

SCHEMBL7814976

O=C(O)c1ccccc1NC(=O)C1CCCCC1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.68
HPGD P15428 2/20 0.68
KDM4E B2RXH2 2/20 0.68
HSD17B10 Q99714 2/20 0.68
NPSR1 Q6W5P4 1/20 0.68
CETP P11597 1/20 0.65
HDAC3 O15379 1/20 0.65
HDAC1 Q13547 1/20 0.65
HDAC2 Q92769 1/20 0.65
LMNA P02545 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.60
ABCC1 P33527 2/20 0.59
RXFP1 Q9HBX9 3/20 0.59
P2RX7 Q99572 2/20 0.57
SIRT2 Q8IXJ6 1/20 0.57
TSHR P16473 1/20 0.57
GAA P10253 1/20 0.56
RXFP2 Q8WXD0 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11732563 1.00 ALDH1A1 (0.68) ALDH1A1HPGDKDM4EHSD17B10NPSR1
SCHEMBL11734795 0.98 ALDH1A1 (0.70) ALDH1A1HPGDKDM4EHSD17B10NPSR1
SCHEMBL11729230 0.95 ALDH1A1 (0.66) ALDH1A1HPGDKDM4EHSD17B10NPSR1
SCHEMBL14855799 0.94 ALDH1A1 (0.70) ALDH1A1HPGDKDM4EHSD17B10NPSR1
SCHEMBL28170369 0.92 ALDH1A1 (0.60) ALDH1A1HPGDKDM4EHSD17B10NPSR1
SCHEMBL16404476 0.92 ALDH1A1 (0.60) ALDH1A1HPGDKDM4EHSD17B10NPSR1
SCHEMBL11594561 0.86 CETP (0.56) ALDH1A1HPGDKDM4EHSD17B10NPSR1
SCHEMBL28256535 0.86 CETP (0.77) ALDH1A1HPGDKDM4EHSD17B10NPSR1
SCHEMBL12323604 0.86 CETP (0.77) ALDH1A1HPGDKDM4EHSD17B10NPSR1
SCHEMBL28258088 0.86 CETP (0.77) ALDH1A1HPGDKDM4EHSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2844345-B1 MODULATORS OF THE RELAXIN RECEPTOR 1 US HEALTH (US) 2022-08-03 EP disclosed
CN-109232275-B Preparation method of 4-nitrodiphenylamine and 4-nitrosodiphenylamine 科迈化工股份有限公司 2021-06-11 CN disclosed
US-10125112-B2 Modulators of the relaxin receptor 1 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-11-13 US disclosed
US-20170144984-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) 2017-05-25 US disclosed
US-20170144984-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) 2017-05-25 US disclosed
US-20170144984-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) 2017-05-25 US disclosed
US-9452973-B2 Modulators of the relaxin receptor 1 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-09-27 US disclosed
US-9452973-B2 Modulators of the relaxin receptor 1 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-09-27 US disclosed
US-9452973-B2 Modulators of the relaxin receptor 1 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-09-27 US disclosed
EP-3049388-A1 THERMOPLASTIC POLYMER COMPOSITION Milliken & Company (US) 2016-08-03 EP disclosed
US-5935601-A Modified amino acids for drug delivery EMISPHERE TECHNOLOGIES, INC. (US) 1999-08-10 US disclosed
EP-0812212-A4 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECH INC (US) 1999-04-14 EP disclosed
EP-0758843-A4 MODIFIED AMINO ACIDS FOR DRUG DELIVERY EMISPHERE TECH INC (US) 1998-05-20 EP disclosed
US-5709861-A PEPTIDES WITH ANTIGENS AND PROCESS FOR MIXING EMISPHERE TECHNOLOGIES, INC. (US) 1998-01-20 US disclosed
EP-0812212-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS Emisphere Technologies, Inc. (US) 1997-12-17 EP disclosed
US-5629020-A Modified amino acids for drug delivery EMISPHERE TECHNOLOGIES, INC. (US) 1997-05-13 US disclosed
EP-0758843-A1 MODIFIED AMINO ACIDS FOR DRUG DELIVERY Emisphere Technologies, Inc. (US) 1997-02-26 EP disclosed
WO-1996021464-A9 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS 1996-11-14 WO disclosed
WO-1996021464-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECHNOLOGIES, INC. (US) 1996-07-18 WO disclosed
WO-1995028838-A1 MODIFIED AMINO ACIDS FOR DRUG DELIVERY EMISPHERE TECHNOLOGIES, INC. (US) 1995-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10125112-B2 Modulators of the relaxin receptor 1 RXFP1, RXFP2, RXFP3 ALDH1A1 2561/4885HPGD 1000/4885KDM4E 4395/4885
US-20170144984-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 RXFP1, RXFP2, RXFP3 ALDH1A1 2561/4885HPGD 1000/4885KDM4E 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.